U.S., March 28 -- ClinicalTrials.gov registry received information related to the study (NCT07498205) titled 'Comparing Momelotinib and Ruxolitinib in People With Untreated Myelofibrosis and Low Blood Cell Counts' on March 20.
Brief Summary: The purpose of this study is to compare momelotinib and ruxolitinib as treatments for myelofibrosis with low blood cell counts. Both drugs are approved by the FDA to treat myelofibrosis. The study asks which drug does a better job at shrinking the spleen.
Study Start Date: Aug. 08, 2026
Study Type: INTERVENTIONAL
Condition:
Myelofibrosis
Myelofibrosis (MF)
Intervention:
DRUG: Momelotinib
200 mg daily x 96 weeks.
DRUG: Ruxolitinib
Twice daily per treating investigator discretion not to exceed p...